• OPEN AN ACCOUNT
Indian Indices
Nifty
24,008.00 -265.80
(-1.10%)
Sensex
79,454.47 -880.34
( -1.10%)
Bank Nifty
53,595.25 -770.40
( -1.42%)
Nifty IT
35,880.10 -122.35
( -0.34%)
Global Indices
Nasdaq
41,266.30 -123.15
(-0.30%)
Dow Jones
5,680.75 -4.19
(-0.07%)
Hang Seng
37,492.25 563.62
(1.53%)
Nikkei 225
8,554.80 23.19
(0.27%)
Forex
USD-INR
85.39 0.69
(0.81%)
EUR-INR
96.28 0.21
(0.22%)
GBP-INR
113.48 0.52
(0.46%)
JPY-INR
0.59 0.00
(-0.21%)

EQUITY - MARKET SCREENER

Kay Cee Energy & Infra Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
92425
INE0RCG01017
56.9813482
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
KCEIL
46.04
311.22
EPS(TTM)
Face Value()
Div & Yield %
5.53
10
0
 

Divis Lab spurts as broker maintains buy call
Apr 24,2025
In its latest note, the broker highlighted Divi’s strong potential to emerge as a primary supplier, backed by ongoing capacity expansion. It also noted the addition of Orforglipron—Eli Lilly’s promising oral GLP-1 candidate—to Divi’s development pipeline. The report further anticipates additional rounds of capital expenditure as product volumes scale up through 2030.

Divi's is engaged in manufacturing of generic APIs, custom synthesis of active ingredients for innovator companies, other specialty chemicals and nutraceuticals. The company is focused on export markets within the domain of its capabilities.

Divi’s Laboratories' consolidated net profit surged 64.53% to Rs 589 crore on 25.01% rise in revenue from operations to Rs 2,319 crore in Q3 FY25 over Q3 FY24.